Research programme: autoimmune disorders and transplant rejection - Bristol-Myers Squibb/GTC

Drug Profile

Research programme: autoimmune disorders and transplant rejection - Bristol-Myers Squibb/GTC

Alternative Names: Autoimmune disorders and transplant rejection research programme: Bristol-Myers Squibb/GTC

Latest Information Update: 21 Feb 2013

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; GTC Biotherapeutics
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Autoimmune disorders; Transplant rejection

Most Recent Events

  • 04 Jan 2013 GTC Biotherapeutics is now called rEVO Biologics
  • 18 Jun 2002 Genzyme Transgenics Corporation is now called GTC Biotherapeutics
  • 09 Dec 1999 Preclinical development for Autoimmune disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top